-
Health Canada approves Alhemo (concizumab) for FIX inhibitors
Montreal – May 23, 2023 – The Canadian Hemophilia Society has learned that Health Canada recently approved Alhemo (concizumab) for the treatment of people, ages...
-
Update on coagulation products – current and in the pipeline
To access charts informing you of products in the PIPELINE, please CLICK HERE. To access charts informing you of CURRENT coagulation products, please CLICK HERE....
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia Consortium.
-
Results of CHS survey on gene therapy
This past summer, the Canadian Hemophilia Society (CHS) conducted an on-line survey on attitudes to and knowledge about gene therapy. The results were presented and...
-
Héma-Québec tender selects an extended half-life FVIII
Héma-Québec announced on November 30, following its Request for Proposals for recombinant factor VIII concentrates, that it had selected Esperoct. Esperoct is approved by Health...